Valion Bio (VBIO) Net Equity Issued and Repurchased (2023 - 2025)

Valion Bio has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $429000.0 in Q3 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 113.2% year-over-year to $429000.0 in Q3 2025; TTM through Dec 2025 was -$2.8 million, a 364.98% decrease from a year earlier, with the FY2025 full-year figure at $2.3 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased was $429000.0 for Q3 2025 at Valion Bio, up from -$3.3 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $4.3 million in Q3 2023, with the low at -$3.3 million in Q3 2024.
• Average Net Equity Issued and Repurchased over 3 years is $1.4 million, with a median of $2.3 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased tumbled 175.32% in 2024, then jumped 113.2% in 2025.
• Over 3 years, Net Equity Issued and Repurchased stood at $4.3 million in 2023, then plunged by 175.32% to -$3.3 million in 2024, then jumped by 113.2% to $429000.0 in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $429000.0 (Q3 2025), -$3.3 million (Q3 2024), and $4.3 million (Q3 2023), per Business Quant data.